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ACTIVATION OF SIGNAL PROTEINS BY INSULIN AND
SELENATE IN PRIMARY RAT HEPATOCYTES
Ginny Lynn Garlock, M.S.
Western Michigan University, 1997
Insulin has a wide range of metabolic and mitogenic effects in cells. The
mechanism of insulin action in controlling these events is not well understood, but
involves, at least in part, a complex phosphorylation cascade.

Selenate has been

shown to mimic insulin on several metabolic processes, including the regulation of
glucose-6-phosphate dehydrogenase (G6PDH) gene expression. Its mechanism of
action, however, is not known. To investigate the mechanisms of insulin and selenate
action on the regulation of G6PDH, signal proteins from primary rat hepatocytes were
first studied. Insulin and sodium selenate similarly increased tyrosyl phosphorylation
of the J3-subunit of the insulin receptor and insulin receptor substrate- I, as determined
by Western analysis.

Insulin and selenate also significantly increased mitogen

activated protein (MAP) kinase activity, as determined by an in-gel activity assay,
through a Ras-dependent pathway. Insulin's effects were typically rapid and transient,
whereas selenate's effects were delayed in onset and sustained for hours. MAP kinase
activation did not appear to be required for insulin-induced G6PDH expression, and
expression may not be due to a rapamycin-sensitive pathway. Selenate induction of
G6PDH expression was sensitive to the effects of rapamycin.
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INTRODUCTION
Insulin Action
f3-cells in the islets of Langerhans synthesize insulin, a pancreatic polypeptide
hormone. Insulin is secreted in response to high blood glucose levels, inducing a
diverse range of metabolic and mitogenic responses which vary among cell types, dose
responses, and time courses of action, among other factors. Insulin is capable of
producing generalized effects on all cell types, such as regulation of gene expression,
cell growth, and DNA synthesis. Alternatively, insulin can result in more specific
effects on the insulin-responsive tissues, muscle, liver, and adipose, such as stimulation
of ion transport, carbohydrate metabolism, and fatty acid metabolism (Figure 1).
As mentioned above, insulin effects many aspects of carbohydrate metabolism,
including positive regulation of glucose-6-phosphate dehydrogenase (G6PDH) gene
expression (Kletzein et al., 1994), one of the enzymes involved in glucose
homeostasis. G6PDH is a rate-limiting enzyme in the pentose phosphate pathway, a
pathway which is of major importance in carbohydrate metabolism in the liver since
one half of the available glucose-6-phosphate can be shuttled through it. This pathway
also produces reducing equivalents in the form of NADPH for anabolic processes,
such as fatty acid biosynthesis, and for reduction of glutathione.
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Figure 1. Effects of Insulin on Cellular Processes. (Modified from Myers & White,
1996).

In order to exert its effects on any cellular process, insulin must transmit its
message from the extracellular fluid, into the cell, and often to the nucleus. The
mechanism of insulin action is not well understood, but involves, at least in part, a
complex phosphorylation cascade. The signal transduction pathway of insulin begins
with insulin binding to its membrane receptor and activation of its kinase activity
(Figure 2). The insulin receptor phosphorylates a number of substrates, including
insulin receptor substrate- I (IRS-1) and She.

Downstream targets include the

mitogen-activated protein (MAP) kinase cascade and the phosphatidylinositol (Pl) 3kinase pathway.
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Figure 2. The Insulin Signaling Pathway.
Insulin Signaling
Insulin Receptor
Insulin binds to its plasma membrane receptor to set off the chain of events that
leads to insulin action.

The insulin receptor is composed of two a. and two

f3
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glycosylated protein subunits linked by disulfide bonds to form a heterotetramer
(White & Kahn, 1994; Lee & Pilch, 1994; Kahn et al., 1993; Myers & White, 1996).
The a-subunit, apparent molecular weight (Mr) of 135,000, is entirely extracellular,
and it is responsible for the high affinity binding of insulin (Yip, 1992). The �-subunit,
Mr 95,000, is a transmembrane protein specialized for signal transduction (White &
Kahn, 1986).
The intracellular portion of the �-subunit is comprised of four distinct
functional domains. One domain is an ATP binding domain essential for kinase
activity (Chou et al., 1987), whereas the remaining three domains are capable of
autophosphorylation upon insulin stimulation and include the juxtamembrane domain,
the regulatory domain, and the C-terminal domain. The juxtamembrane domain,
containing the residues Tyr96°, Tyr953, and Tyr972, is important in receptor substrate
binding (White et al., 1988). The regulatory domain, containing the residues Tyr1146,
.
Tyr u5o, and Tyr1151 , 1s
• Important
•
.
. of the receptor tyrosine kinase
m
the regu1at10n
activity (Tavare et al., 1988). The function of the C-terminal domain, containing
residues Tyr1316 and Tyr1322 (Tavare et al., 1988), is unknown at this time, but it may
play some sort of regulatory role on the tyrosine kinase activity upon phosphorylation
(Takata et al., 1991).
It is not certain what is happening at the molecular level to activate the insulin
receptor following insulin binding (Kahn et al., 1993);

however, extensive data

suggests the receptor acts as a classic allosteric enzyme as it undergoes conformation
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and phosphorylation modifications. In unstimulated cells, the a-subunit suppresses the
tyrosine kinase activity of the f3-subunit.

Upon insulin binding to the a-subunit,

conformational changes of the receptor take place, altering the ability of the a-subunit
to suppress kinase activity. The subsequent increase in kinase activity stimulates
autophosphorylation through a trans mechanism. All three of the tyrosine residues in
the regulatory domain previously mentioned require phosphorylation for full activation
of the kinase activity.

This phosphorylation further modifies the conformation

enabling tyrosine autophosphorylation in the juxtamembrane and C-terminal domains.
With these tyrosine residues phosphorylated, the insulin receptor is now able to
phosphorylate its substrates.
Substrates of the Insulin Receptor
Although the insulin receptor tyrosine kinase activity had been fairly well
established by 1985, a direct insulin receptor substrate still remained to be identified.
The evidence for this substrate came about with the development of anti
phosphotyrosine antibodies (White et al., 1985) which identified a phosphoprotein of
185 kDa known as IRS-1.
IRS-1 is a cytoplasmic protein that associates with the insulin receptor during
stimulation (Sun et al., 1992). IRS-1, containing 21 potential tyrosine phosphorylation
sites (White & Kahn, 1994; Kahn et al., 1993; Myers & White, 1996), acts as a multi
site "docking" protein for signaling molecules which associate with distinct amino acid
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motifs. Of the 21 potential phosphorylation sites, six have a YMXM amino acid motif,
and three have a YXXM motif, while the remaining sites are other various
hydrophobic motifs.

The insulin receptor phosphorylates at least eight tyrosine

residues on IRS- I .

Four of these residues are found with the YMXM motif

Associations with phosphorylated IRS-I occur through the src homology 2 (SH2) and
src homology 3 (SH3) domains of the signaling molecules.

These noncatalytic

domains are conserved among many signaling proteins and function as adapter sites,
allowing proteins to transiently associate without covalent attachment (Koch et al.,
1991). Both PI 3-kinase (Myers et al., 1992) and growth factor receptor-bound
protein 2 (GRB2) (Skolnik et al., 1993) are two proteins which bind to
phosphorylated YMXM motifs of IRS- I through SH2 domains upon insulin
stimulation.
In addition to tyrosine phosphorylation sites, IRS-I also contains over 30
potential serine/threonine phosphorylation sites in the human. IRS- I is highly serine
phosphorylated, but sparsely threonine phosphorylated in its basal state.

Insulin

stimulation greatly enhances the serine phosphorylation. The significance of this
modification is not yet known.
Another family of substrates of the insulin receptor has also been identified, the
She family. This family of phosphoproteins consists of at least three isoforms ranging
from 46 to 52 kDa (Myers & White, 1996). She proteins are SH2 domain-containing
proteins that have a region homologous with a I-collagen, from which the name was
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derived (Pronk et al., 1993). Upon stimulation with a number of growth factors,
including insulin (Kovacina & Roth, 1993), She becomes tyrosine phosphorylated.
Both IRS-I and She bind SH2 domains of the adapter protein GRB2. Rat 1
fibroblasts overexpressing the insulin receptor show different kinetics for the
associations of GRB2 to She or to IRS-I (Sasaoka et al., 1994). Although the
kinetics vary, both She and IRS-I compete for a limited pool of GRB2 in CHO cells
overexpressing the insulin receptor (Yamauchi & Pessin, 1994). GRB2 is essential in
the transmission of signal between tyrosine kinases and an important downstream
target, Ras (Clark et al., 1992). In insulin-stimulated cells it appears that a guanine
nucleotide exchange factor, Sos (for Son of sevenless), activates Ras proteins
following association of the C-terminal region of with SH2 domains of GRB2
(Chardin et al., 1993).
MAP Kinase Cascade
The MAP kinase cascade is a pathway central to cellular responses to many
growth and stress stimuli, including insulin (Seger et al., 1995; Ferrell, 1996). It has
been a primary focus of research in recent years. One way MAP kinases become
activated is through GTP-bound Ras. Sos exchanges the nucleoside triphosphate GTP
for GDP bound to Ras, changing the conformation of the complex. The Ras-GTP
conformation is the "active" conformation, being able to activate downstream
signaling targets (Maruta & Burgess, et al., 1994).

Ras has been found to be
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important

m

signal

transduction

pathways

involving

growth

stimulation,

transformation, proliferation, and differentiation (Satoh et al., 1992).
In addition to nucleotide exchange, the activation process of Ras requires
farnesylation in order for Ras to interact with the plasma membrane (Gibbs, 1991).
Enzyme inhibitors have been instrumental in determining involvement of Ras, among
numerous other signaling molecules, in signal transduction mechanisms. Inhibitors
effectively "knock out" pathways or branches of pathways through prevention of
downstream events, and therefore, one can determine potential pathways used by
stimulatory agents.

Lovastatin, a compound used extensively in treatment of

cholesterol disorders, inhibits the farnesylation of Ras (McGuire et al., 1993; Xu et
al., 1996) by inhibiting isoprenoid synthesis through competitive inhibition of HMG
CoA (Goldstein & Brown, 1990).

Without proper Ras activation, downstream

signaling events are limited.
Activation of Ras begins a cascade that results in MAP kinase activation. Ras
is necessary for Raf-1 activation (Williams et al., 1992), but is not sufficient. Ras
recruits Raf- I to the membrane where it is activated by an unknown mechanism. This
activation allows the serine/threonine kinase activity of Raf- I to phosphorylate and
activate MAP kinase kinase (MEK) (Kyriakis et al., 1992). MEK is the preferred
substrate of Raf- I. Phosphorylation on serine residues activates MEK, which then
phosphorylates MAP kinase on threonine and tyrosine residues, both types of which
are required for full enzymatic activity (Anderson et al., 1990).

Threonine and
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tyrosine phosphorylation of MAP kinase activates the serine/threonine kinase activity
of this enzyme (Crews & Erikson, 1992).
There are at least two isoforms of MAP kinase, p42 and p44 (Boulton et al.,
1991). A series of irnmunofluorescence experiments demonstrated that growth factor
stimulation causes both isoforms to rapidly translocate to the nucleus while MEK
remains in the cytoplasm (Lenormand et al., 1993). The fact that MAP kinase can
translocate to the nucleus potentially links MAP kinase to insulin's nuclear events like
DNA synthesis and gene expression. Within the nucleus are transcription factors like
Elk-I that are substrates of MAP kinase (Whitmarsh et al., 1995).

Besides

transcription factors, other kinases and phosphatases are substrates, such as the serine
kinases of the 90 kDa kinase family of the S6 kinases, (Sturgill et al., 1988). These
substrates give rise to some of the known physiological roles of MAP kinase including
cell proliferation, oncogenesis, development and differentiation, and cell cycle
involvement.
Phosphatidylinositol 3-Kinase
IRS-I has been shown to activate the PI 3-kinase pathway. PI 3-kinase is
composed of a Mr 110,000 catalytic subunit (pll0) (Hiles et al., 1992) and an Mr
85,000 regulatory subunit (p85) (Otsu et al., 1991).

p85, containing two SH2

domains flanking a SH3 domain, strongly associates with tyrosyl phosphorylated IR.S
I following insulin stimulation, activating the kinase activity of p l IO (Backer et al.,
1992).

Activation allows PI

3-kinase

to phosphorylate a

variety

of

10
phosphatidylinositol substrates at the 3 position of the inositol ring (Auger et al.,
1989).
At least two significant events have been linked to PI 3-kinase activation. One
of these is glucose transport. Upon PI-3 kinase activation, GLUT 4 transporters
translocate to the plasma membrane.

Some of the evidence for PI-3 kinase

involvement in glucose transport came about from the use of wortmannin, a fungal
metabolite that inhibits PI 3-kinase (Powis et al., 1994). GLUT 4 is a glucose
transporter found in muscle cells and adipocytes that is stimulated by insulin.
Wortmannin did inhibit GLUT 4 translocation, suggesting that PI 3-kinase is involved
in glucose effects of insulin (Kanai et al., 1993).
In addition to affecting glucose transport, PI-3 kinase activates S6 kinase
through a mechanism that is not clear. S6 kinases phosphorylate ribosomal protein S6
following mitogen stimulation (Sturgill & Wu, 1991). PI 3-kinase activates the 70
kDa species of S6 kinases. Rapamycin is an immunosuppressant that has been found
to inhibit the activation of S6 kinase (Price et al., 1992) by affecting an intermediate in
this cascade upstream of this protein. Rapamycin has been used extensively in studies
of insulin signaling to determine involvement of S6 kinase in glycogen synthase activity
(Shepard et al., 1995), phosphoenolpyruvate carboxykinase gene expression
(Sutherland et al., 1995), and glucose transporter activity (Moule et al., 1995).
Selenium
Selenium is an essential trace element with several biological effects (Bedwal et
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al., 1993). It is necessary for growth, as is demonstrated by diseases produced from
selenium deficiency, and is an essential component of many metalloenzymes in the
form of selenocysteine.

Selenium has been studied at length for therapeutic and

protective functions. Current research shows selenium as a potential treatment of
some forms of cancers (Clark et al., 1996). Selenium also has important antioxidant
properties (Rana & Verma, 1997).
Selenium, in the form of selenate, has been found to mimic insulin on several
metabolic processes.

Selenate regulates gene expression of two insulin-regulated

enzymes, fatty acid synthase and G6PDH in a similar manner to that of insulin (Berg et
al., 1995).

Selenate lowers blood glucose levels similarly to insulin as seen in

streptozocin-induced diabetic rats (Berg et al., 1995; McNeil} et al., 1991), as well as
stimulates glucose transporter activity, cAMP phosphodiesterase activity, and
ribosomal S6 kinase activity in adipocytes (Ezaki, 1990).
Not much is known about how selenium elicits its effects in terms of signaling.
Selenium has been found to stimulate tyrosine phosphorylation of several endogenous
proteins in adipocytes, without activating the insulin receptor kinase activity (Ezaki,
1990). Selenium, in the form of selenate, also enhanced tyrosine phosphorylation by
insulin in NIH 3T3 HIR3.5 cells (Pillay & Makgoba, 1992) and adipocytes (Ezaki,
1990).
Objective of the Study
Selenium mimics insulin on a number of metabolic processes, but not much is
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known about how selenium accomplishes its effects. The goal of this study was to
determine if selenium elicits its insulin-mimetic effects through a similar signaling
cascade as that of insulin. The model system chosen was primary rat hepatocytes,
which respond similarly to insulin as whole animals. First, an attempt was made to
look at the signaling cascade was by studying tyrosyl phosphorylation of insulin and
selenate stimulated hepatocytes, focusing on the 13-subunit of the insulin receptor and
IRS-1. Next, the activity of MAP kinase was investigated, as well as the effect that
inhibition of the upstream signal protein Ras had on this activity. Lastly, the effects of
wortmannin, rapamycin and lovastatin on insulin and selenate-induced G6PDH
expression were compared.

MATERIALS AND METHODS
All materials, unless specifically noted, were purchased from Sigma Chemical
Company (St. Louis, MO) and were of tissue culture grade where applicable.
Hepatocyte Isolation and Cell Culture
Male Sprague-Dawley rats (Harlan Sprague-Dawley, Kalamazoo, MI)
weighing 200-300 g were fasted 48 h prior to hepatocyte isolation. Hepatocytes were
isolated using collagenase, hyaluronidase perfusion as described (Elliget & Kolaja,
1983) with the following modifications. After collagenase perfusion, the liver was
removed and gently forced through four layers of sterile gauze.

The cells were

washed two times with cold Waymouth's MB 752/1 medium (Gibco BRL, Grand
Island, NY) supplemented with 5% bovine serum albumin (BSA) and pelleted for 3
min at 4° C and 50 x g. The cell pellet was resuspended in medium and an aliquot of
cells was counted with a hemocytometer. Cell viability was determined by trypan blue
dye exclusion. Cells from isolations yielding less than 70% viable hepatocytes were
discarded.
Falcon 60 mm tissue culture dishes were collagen coated with 0.2 mg/ml of rat
tail collagen (Collaborative Biomedical Products, Bedford, MA) and left overnight
under ultraviolet light. Hepatocytes were plated at approximately 3.0 x 106 cells/plate
in Waymouth's MB 752/1 medium supplemented with 10 µg/ml gentamicin and 5%
13
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BSA under a humidified atmosphere of 5% CO2 at 37 C. After 3-4 h of incubation,
the cells were washed once with serum-free, BSA-free Waymouth's medium, and fresh
serum-free, BSA-free medium was added for further incubation. Cells were treated
with insulin (a gift from Eli Lilly Corp., Indianapolis, IN), sodium selenate, or enzyme
inhibitors within 24 h of isolation according to the time periods and concentrations
indicated in Results.

Hepatocytes used in experiments involving inhibitors were

treated with the inhibitors prior to insulin or selenate addition. Cells were pretreated
with lovastatin (Merck, Rahway, NJ) for 24 h, rapamycin (Calbiochem, La Jolla, CA)
for 30 min, wortmannin for 30 min, and okadaic acid for 30 min. These times were
chosen based on use of these inhibitors in other documented studies.
Cell Harvest
For G6PDH assays, treated hepatocytes were incubated 42-48 h. Following
aspiration of media, two 60 mm plates for each condition were scraped in KED buffer
consisting of 0.1 M potassium phosphate buffer, pH 7.0, 3 mM ethylenediamine
tetraacetic acid (EDTA), and 1 mM dithiothreitol (DTT).

Hepatocytes were

homogenized with 25 strokes in a Dounce homogenizer, and the resulting cellular
extracts were centrifuged for 10 min at 4°C and 10,000 x g. Supematants were
removed and stored at -20° C.
One 60 mm plate per condition was utilized for kinase and phosphatase assays
as well as Western analysis, while two 60 mm plates were pooled for the MAP kinase
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activity assay. Hepatocytes for these assays were then processed as follows. Cells
were washed three times in ice-cold phosphate-buffered saline (PBS), pH 7.4, and
scraped into a lysis buffer composed of 20 mM N-[2-hydroxyethyl]piperazine-N'-[2ethanesulfonic acid] (HEPES), pH 7.3, 100 mM NaCl, 0.5% Triton X-100, 10 mM
MgCh, 10 mM �-glycerophosphate, 5 mM p-nitrophenolphosphate, 1 mM EDTA, I
mM ethylene glycol-bis(�-aminoethyl ether) N,N,N',N'-tetracetic acid (EGTA), 1 mM
sodium vanadate, 1 mM OTT, 1 mM phenylmethylsulfonylfluoride (PMSF), 1 mM
NaF, 5 µg/ml leupeptin, and 5 µg/ml pepstatin. The total cell extracts were briefly
vortexed and centrifuged for 10 min at 4° C and 10,000 x g. The supernatant was
removed, quick frozen in a dry ice/isopropanol bath, and stored at -70° C.
Total Protein Determination and Assay of G6PDH Activity
Total protein concentrations were determined by the Lowry method (Lowry,
\

1951). G6PDH activity was measured spectrophotometrically by the rate of change of
NADPH absorbance at 340 nm as described by Berg et al. (1995). Specific G6PDH
activity was calculated by change in absorbance per µg protein multiplied by the
extinction coefficient of the reaction.
Western Analysis
Western analysis was done with total cellular extracts, immunoprecipitated
IRS-I from cellular extracts, and semi-purified insulin receptors from cellular extracts.

16
IRS-1 was immunoprecipitated according to manufacturer's instructions. Briefly, 4 µg
of anti-rat carboxy-terminal IRS-1 (Upstate Biotechnology Incorporated, Lake Placid,
NY) was added to cellular extracts diluted to 1 µg/µl (500-1000 µg total protein) and
incubated with rotation overnight at 4° C. The immunocomplex was captured by
addition of 100 µl of Protein A agarose (Gibco BRL), followed by a two hour
incubation period at 4° C. The agarose beads were collected by brief centrifugation
and washed three times with ice-cold PBS, pH 7.4. The beads were resuspended in
SDS-PAGE sample buffer.
Insulin receptors were semi-purified by adsorption to wheat germ lectin
sepharose beads (Pharmacia Biotech Inc., Piscataway, NJ). Total cellular lysate was
added to 200 µl of beads and incubated with rotation at 4° C for 1 h. Beads were
briefly pelleted with centrifugation and washed 4-5 times with wash buffer (50 mM
HEPES, pH 7.6, 0.15 M NaCl, 0.05% SDS). Insulin receptors were eluted with 50 µl
of elution buffer [0.15 mM Tris-HCl, pH 7.6, 4.7% SDS, 24% glycerol, 0.71 M 13mercaptoethanol (13-ME), and 0.3 M N-acetylglucosamine] by incubation with rotation
at 4° C for 15 min. Receptors were collected in the supernatant following brief
centrifugation.
For Western analysis, either SOS-PAGE sample buffer was added to 5-10 µg
of protein from the cellular lysates or equal volumes were taken from the semi
purification of the insulin receptor and IRS-1 immunoprecipitation. The samples were
boiled for 5 min, electrophoresed on a 10% polyacrylamide, and transferred to PVDF
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membrane (DuPont NEN, Boston, MA) using semi-dry electroblotting techniques as
described by the manufacturer, NOVEX (San Diego, CA). Following transfer, the
membrane was blocked with 5% BSA in PBS, pH 7.5, containing 0.1% Tween 20.
After blocking, the membrane was incubated first with anti-phosphotyrosine antibody
(clone 4G10, Upstate Biotechnology Incorporated) diluted 1:2000 in PBS containing
0.1% Tween 20, and then incubated with anti-mouse IgG conjugated to horseradish
peroxidase (Amersham, Arlington Heights, IL) diluted 1 :3500 in PBS containing 0.1%
Tween 20. lmmunoreactive bands were detected on Hyperfilm (Amersham) with an
enhanced chemiluminescence Western blotting detection system according to the
manufacturer's protocol (Amersham).
Tyrosine Kinase and Serine/Threonine Phosphatase Assays
Tyrosine kinase and serine/threonine phosphatase activities were evaluated
with protein tyrosine kinase and protein phosphatase assay systems, respectively,
according to manufacturer's instructions (Gibco BRL). The tyrosine kinase assay
system contained a 13 amino acid synthetic peptide derived from the phosphorylation
site of pp60src.

Briefly, 10 µl cellular extracts (50-100 µg total protein) were

incubated with 0.5-1 µCi of [y-32P] ATP (Dupont NEN) and the peptide substrate for
30 min at 30° C.

The reaction was quenched with ice-cold 10% TCA.

After

incubation on ice for 10 min, samples were centrifuged in a microcentrifuge for 10 min
at 4° C. Supematants (20 µl) were spotted onto phosphocellulose disks and washed
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first with I% acetic acid then with water. Incorporation of the label was measured by
scintillation counting.
The protein phosphatase assay system measured activity of the serine/threonine
phosphatases PP-I and PP-2A on glycogen phosphorylase a.
inhibitor of these phosphatases, was utilized.

Okadaic acid, an

Okadaic acid was either added to

hepatocytes and allowed to incubate, or, as a control, it was added directly to the
reaction tube and incubated for a brief incubation period immediately before assay.
Assays were performed as follows. Radiolabeled phosphorylase a was generated by
the incubation of phosphorylase kinase in the presence of phosphorylase b and O.5 mCi
of [y-32P] ATP for I h at 30°C. The reaction was quenched with 90% saturated
ammonium sulfate and washed with a I :2 dilution of the ammonium sulfate solution.
The precipitated substrate was resolubilized in a supplied buffer [50 mM Tris-HCI, pH
7.0, 0.1 mM EDTA, 15 mM caffeine, 0.1% (v/v) f3-ME] and concentrated in a protein
concentrator (Amicon, Centricon-30) centrifuged at 5000 x g for 20-30 min at 20°C.
In short, the assay proceeded as follows. Cellular extracts (20 µl, 100-200 µg total
protein) were incubated with the 32P-labeled substrate for 10 min at 30°C. Reactions
were quenched with addition of ice-cold 20% TCA and then incubated on ice for I0
min. Following centrifugation in a microcentrifuge for 3 min at 4°C, phosphatase
activity was determined by scintillation counting of the liberated 32P-labeled phosphate
found within the supernatant.

MAP Kinase Activity Assay
MAP kinase activity was analyzed using an in-gel activity assay with myelin
basic protein (MBP) as a substrate (Tobe et al., 1992) with the following
modifications. Samples were suspended in SOS-PAGE sample buffer and boiled for 5
min. Equal volumes of samples, containing roughly 60-120 µg total protein, were
electrophoresed in a 12% polyacrylamide gel containing 0.55 mg/ml MBP (Gibco
BRL).

After electrophoresis the gel was washed sequentially in the following

solutions:

Buffer B (50 mM Tris pH 8.0 and 5 mM P-ME) containing 20%

isopropanol, Buffer B only, and then Buffer B containing 6 M guanidine HCl. After
denaturation, the gel was washed in Buffer B containing 0.04% Triton X-100 and then
in Buffer E (40 mM HEPES pH 8.0, 2 mM DTT, and 10 mM MgCh). Finally, the gel
was incubated with 40 µM [y-32P] ATP in Buffer E, rinsed in 5% TCA and 1% sodium
pyrophosphate, dried, and exposed to X-OMAT AR film (Eastman Kodak Company,
Rochester, NY). Densitometric scanning results were equalized for protein amounts.
Densitometric Scanning
Images of Western blots and MAP kinase autoradiographs were captured and
quantitated by densitometric scanning on Image-1/MetaMorph, Version 2 (Universal
Imaging Corporation). Images were scanned from autoradiographs by a Hewlett
Packard Scanjet5p using Paperport (Visioneer, Incorporated), Version v.B, followed
by modification in Corel PhotoPaint Select (Corel Corporation), Version 5.00.F4.
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Final images were imported into document and printed by Microsoft Word (Microsoft
Corporation), Version 97.
Statistical Analysis
The results are expressed as the mean± S.E.M. Significance was evaluated by
one-tailed Student's t-test and tested at p<0.05.

RESULTS
Insulin and Selenate Induction of Tyrosine Phosphorylation
Cells from insulin-sensitive tissues exhibit a rapid increase in tyrosine
phosphorylated proteins in response to insulin (Myers & White, 1996; Kahn et al.,
1993). In order to determine whether this insulin-induced increase occurs in primary
rat hepatocytes, Western analysis was performed with whole cell lysates using anti
phosphotyrosine antibody. Figure 3 shows a representative blot of the time course of
insulin-stimulated tyrosine phosphorylation. Hepatocytes treated with 80 nM insulin
for 1 min, 5 min, 15 min, or 30 min exhibited rapid tyrosyl phosphorylation of a
number of endogenous proteins, including protein bands that migrated at the apparent
molecular weights of the P-subunit of the insulin receptor and IRS-1. Phosphorylation
of the P-subunit of the insulin receptor increased maximally 2-3 fold, while
phosphorylation of IRS-1 increased by 3-4 fold. Increases in insulin-induced tyrosyl
phosphorylation of the P-subunit of the insulin receptor and IRS-1 have been observed
in many cell types including Fao hepatoma cells (White et al., 1985) and CHO cells
overexpressing the insulin receptor (Sun et al., 1992). Similar to results observed by
others (Kowalski et al., 1983), maximal levels of phosphorylation occurred within five
minutes and then diminished to near basal levels within an hour.

This transient

increase in phosphorylation is most likely due to dephosphorylation by tyrosine
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Figure 3. Effect of Insulin on Tyrosyl Phosphorylation.
Hepatocytes were treated with either nothing (Lane 1 ), or 80 nM insulin
for 1 min (Lane 2), 5 min (Lane 3), 15 min (Lane 4), or 30 min (Lane 5).
Cellular extracts were subjected to Western analysis with anti
phosphotyrosine antibody. Bands corresponding to IRS-1 and the P
subunit of the insulin receptor (P-IR) are shown on the left. Molecular
weight markers are shown on the right.

phosphatases, since known tyrosine phosphatase inhibitors completely abolish the
characteristic decrease in tyrosyl phosphorylation (Kowalski et al., 1983).
Selenate mimics insulin action on a number of metabolic processes.

To

investigate whether selenate mimics insulin action by stimulation of tyrosyl
phosphorylation of similar proteins, hepatocytes were treated with either 250 µM
sodium selenate for 1 h or 3 h, or 500 µM selenate for 5 min, 30 min, 1 h, or 3 h.
Cellular lysates were then analyzed by Western blotting with anti-phosphotyrosine
antibody.

Figure 4 shows a representative blot of the concentration and time-
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dependence of selenate on tyrosine phosphorylation.

Selenate increased tyrosyl

phosphorylation of many endogenous proteins, including bands migrating at the
apparent molecular weights of the J3-subunit of the insulin receptor and IRS-1. These
results agree with a selenate-induced increase in the phosphorylation of a number of
endogenous proteins seen in adipocytes (Ezaki, 1990) and NIH 3T3 HIR.3.5 cells
(Pillay & Makgoba, 1992). Notable increases in tyrosyl phosphorylation appeared at 3
h with 250 µM selenate or 1 h with 500 µM selenate. Phosphorylation of the J3-
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Figure 4. Effect of Selenate on Tyrosyl Phosphorylation.
Hepatocytes were treated with either nothing (Lane 1); 250 µM sodium
selenate for 1 h (Lane 2) or 3 h (Lane 3); or 500 µM sodium selenate for 5
min (Lane 4), 30 min (Lane 5), 1 h (Lane 6), or 3 h (Lane 7). Cellular
extracts were subjected to western analysis with anti-phosphotyrosine
antibody. Bands corresponding to IRS-1 and J3-IR are shown on the left.
Molecular weight markers are shown on the right.

subunit of the insulin receptor, as compared to control cells, increased from
approximately 1.5 fold with 250 µM selenate at 1 h to 3 fold at 3 h; whereas at 500
µM selenate, fold increases changed from 2 fold at 1 h to about 5 fold at 3 h.
Phosphorylation of IRS-1, as compared to control cells, increased from approximately
1.5 fold with 250 µM selenate at 1 h to 3 fold at 3 h; while at 500 µM selenate, fold
increases changed from 2-3 fold at 1 h to about 6 fold at 3 h. Curiously, the level of
tyrosyl phosphorylation in selenate-stimulated cells did not diminish within the time
cou�se tested, but in fact escalated within five hours of incubation.
To generate additional evidence that increases in tyrosyl phosphorylation of the
13-subunit of the insulin receptor and IRS-1 were observed following insulin and
selenate stimulation, insulin receptors and IRS-1 were separated from whole cell
lysates by wheat germ adsorption and immunoprecipitation, respectively.

The

resulting proteins were then subjected to Western analysis with anti-phosphotyrosine
antibody. Hepatocytes incubated with either 80 nM insulin for 5 min or 500 µM
sodium selenate for 1 h had an increase in tyrosyl phosphorylation of the 13-subunit
similar to that seen in the general tyrosyl phosphorylation of whole cell lysates (data
not shown). An increase in tyrosyl phosphorylation of IRS-1 of approximately 3 fold
occurred in hepatocytes stimulated with 80 nM insulin for 5 min, while an increase of
2 fold was seen in cells stimulated with 500 µM selenate for 1 h (Figure 5).
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Figure 5. Effect of Insulin and Selenate on Tyrosyl Phosphorylation of IRS-1.
Hepatocytes were dosed with either nothing (Lane 1), 80 nM insulin for 5
min (Lane 2), or 500 µM sodium selenate for 1 h (Lane 3). IRS-1 was
immunoprecipitated from cellular extracts and subjected to Western
analysis. Tyrosyl phosphorylation was detected by anti-phosphotyrosine
antibody.

Activity of Tyrosine Kinases and Serine/Threonine Phosphatases
Incubation of hepatocytes in the presence of sodium selenate for three or more
hours resulted in a substantial increase in tyrosyl phosphorylation. This increase could
potentially be due to either an increase in tyrosine kinase activity or a decrease in
tyrosine phosphatase activity.

To explore the effect of selenate on kinase and

phosphatase activity, commercially available enzyme activity kits were employed. The
tyrosine kinase kit did not prove effective for our line of study due to technical
problems. Background incorporation of labeled substrate onto phosphocellulose disks
was often higher than that of the samples assayed. Therefore, data was inconclusive
concerning the effect of selenate on tyrosine kinase activity.
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A tyrosine phosphatase kit was unavailable at the time of these experiments, so
a kit analyzing serine/threonine activity of the serine/threonine phosphatases PP-I and
PP-2A was utilized to determine if a decrease in the activity of these phosphatases
could potentially affect overall tyrosyl phosphorylation. Incubation of hepatocytes in
500 µM sodium selenate for either 3 or 5 h had no effect on serine/threonine
phosphatase activity of PP-I and PP-2A as compared to activity of control plates (data
not shown). In addition, 2 mM selenate added in vitro to untreated cells immediately
before assay also did not decrease activity. However, 10 nM okadaic acid, a known
serine/threonine phosphatase inhibitor, inhibited phosphatase activity by over 60%
whether it was incubated with cells or added in vitro immediately before assay (data
not shown).

Thus, selenate does not appear to inhibit the activity of these

phosphatases.
MAP Kinase Activation
The MAP kinase cascade is a common pathway utilized by many growth
factors, including insulin.

To determine if MAP kinase was involved in primary

hepatocyte signaling upon insulin and selenate stimulation, an in-gel kinase activity
assay was used. Figure 6 shows a representative autoradiograph of insulin and
selenate-induced MAP kinase activity. Insulin at 80 nM concentrations incubated for
5 min stimulates an increase in the activity of two isoforms of MAP kinase, p42 and
p44, as compared to control. Insulin increased activity of p44 by 2.3 fold at 5 min.
Measurable MAP kinase activity was not seen before 5 min and rapidly decreased to
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Figure 6. Effect oflnsulin and Selenate on MAP Kinase Activity.
Hepatocytes were treated with either nothing (Lane 1); 80 nM insulin for 5
min (Lane 2); 250 µM sodium selenate for 30 min (Lane 3) or 1 h (Lane
4); or 500 µM sodium selenate for 15 min (Lane 5), 30 min (Lane 6), 1 h
(Lane 7), or 2 h (Lane 8). Cellular extracts were electrophoresed in a
polyacrylamide containing gel containing myelin basic protein as a
substrate. The gel was subjected to a kinase reaction using [y-32P] ATP as
a substrate and bands were visualized by autoradiography. Arrows on the
left indicate the p42 and p44 isoforms of MAP kinase. Arrows on the right
indicate molecular weight markers.

near basal levels within 30 mm.

Increases in MAP kinase activity upon insulin

stimulation have been fairly well-characterized in a variety of cell types (Boulton et al.,
1991; Peak et al., 1993; Tobe et al., 1992).
Selenate also stimulates an increase in p42 and p44 MAP kinase activities in a
time and concentration-dependent fashion. As shown in Figure 7, 500 µM selenate
substantially increased activity of p44 from 5 fold at 30 min to 6.3 fold at 2 h. Since
these fold increases were so much higher than that of insulin stimulation, lower
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concentrations and shorter time points were explored. Cells stimulated with 250 µM
selenate for 15 min increased MAP kinase activity ofp44 3.46 fold (mean ofn=2) over
that of control. In contrast to insulin, selenate continued to increase levels of activity
throughout the time periods tested, up to 3 h.
In insulin-stimulated cells, MAP kinase is activated through the Ras/Raf/MEK
pathway. Since MAP kinase activation occurred as a result of insulin and selenate
stimulation in primary rat hepatocytes, it now became important to determine if the
Ras/Raf/MEK pathway was utilized. In order to accomplish this, an inhibitor of Ras
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Figure 7.

Effect ofInsulin and Selenate on p44 MAP Kinase Activity.
Hepatocytes wete incubated with either nothing (NA), 80 nM insulin
for 5 min, or 500 µM sodium selenate for 30 min, 1 h, or 2 h. MAP
kinase activity was determined with an in-gel activity assay as
described in Materials and Methods. Autoradiographs of p44 were
quantitated by scanning densitometry, equalized for protein amounts,
and compared to NA. Data shown is the mean of the fold increases ±
S.E. ofthe number ofexperiments shown above the bars.
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activation, lovastatin, was used to determine its effects on MAP kinase activity.
Hepatocytes were pretreated with either 0, 2, or 20 µM lovastatin overnight and then
treated with nothing (NA), 80 nM insulin for 5 min, or 500 µM sodium selenate for 1
h. MAP kinase activity was determined by the in-gel activity assay. Autoradiographs
of p44 were quantitated by densitometric scanning, equalized for protein
concentrations, and compared to control plates (NA) for each of the inhibitor
concentrations. The higher the dose of lovastatin, the greater the decrease in p44
MAP kinase activity (Figure 8). Decreases in insulin and selenate stimulated activity
were significant at p<0.05 for 2 µM and 20 µM lovastatin as compared to
unstimulated cells. Xu et al. (1996) also saw a decrease in insulin-stimulated MAP
kinase activation in HIRcB fibroblasts in the presence of lovastatin. Lovastatin did not
appear to have an effect on MAP kinase activity in unstimulated cells.
Effects of Enzyme Inhibitors on G6PDH Activity
Insulin, as well as selenate, upregulates G6PDH expression. It is not known
which pathway is utilized for insulin induction of G6PDH. In addition, it is not known
how selenate stimulates G6PDH expression.

In order to investigate this, several

enzyme inhibitors were employed in an attempt to block certain pathways.
Since an increase in MAP kinase activity had been observed, it was necessary
to determine if G6PDH activity was linked to the MAP kinase cascade. Lovastatin
was tested at 0.01, 0.1, 1, and 10 µM. Hepatocytes were incubated in the absence or
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presence of lovastatin for 24 h and were then either left untreated or treated with 80
nM insulin or 20 µM sodium selenate for 42-48 h. The activities of the control plates
for each inhibitor concentration were arbitrarily set at 100 %, and the effects of
lovastatin with insulin or selenate were expressed as percent of control. A wide range
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Figure 8.
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Effect ofLovastatin on p44 MAP Kinase Activity.
Hepatocytes were incubated with either nothing (NA), 80 nM insulin
for 5 min, or 500 µM sodium selenate for 1 h after a pretreatment
period of 24 h with 0, 2, or 20 µM lovastatin. MAP kinase activity
was determined with an in-gel activity assay as described in Materials
and Methods. Autoradiographs of p44 were quantitated by scanning
densitometry, equalized for protein amounts, and compared to the
respective control inhibitor plates. Data shown is the mean of the fold
increases± S.E. of the number of experiments shown above the bars.
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of concentrations were tested with few complete experimental runs (at most n=2).
General trends were observed, but we did not pursue the effects of lovastatin on
G6PDH activity further. Lovastatin did not appear to have any effect on G6PDH
activity in insulin-treated cells. For every concentration of lovastatin used, insulin
induced increases in G6PDH activity 230 to 260 percent of control, which was no
different from cells incubated without inhibitor.

It could not be determined if

lovastatin affected G6PDH activity in selenate-treated cells. Selenate-induced activity
of G6PDH was uncharacteristically variable for these trial runs, and trends could not
be identified. The percent increases ranged from 170 to 240 percent of control with
no observable pattern.
With evidence against MAP kinase participation in insulin-induced G6PDH
expression, attention turned to investigation of the involvement of the PI 3-kinase
pathway with this expression. Wortmannin has been a useful tool in determining
involvement of PI 3-kinase with metabolic enzymes. Hepatocytes in culture were
incubated in the absence or presence of 1, 10, and 100 nM wortmannin for 30 min and
were then either left untreated or treated with 80 nM insulin or 20 µM sodium selenate
for 42-48 h. The activities of the control plates for each inhibitor concentration were
arbitrarily set at 100 %, and the effects of the inhibitors with insulin or selenate were
expressed as percent of control. Wortmannin decreased G6PDH activity in insulin
stimulated cells by 45% (Table 1). There were statistically significant decreases (p<
0.05) in enzyme activity for each concentration of wortmannin as compared to the
control insulin-stimulated cells. In selenate-stimulated cells, wortmannin decreased
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Table 1
Effect ofWortmannin on G6PDH Activity in Primary Rat Hepatocytes
Treatment

G6PDH activity as % ofcontrol

Ins

243±11 • (3)

Wm 1+Ins

190±29 ° (3)

Wm 10+Ins

134±20 ° (3)

Wm 100+Ins

173±35 ° (3)

Se

186±12·(3)

Wm 1+Se

160 ± 46 (3)

Wml0+Se

144±18 ° (3)

Wm 100+Se

53 (2)

* Significantly different from NA at p<0.05.
D Significantly different from Ins at p<0.05.
0 Significantly different from Se at p<0.05.
Primary rat hepatocytes in culture were incubated in the absence or presence of 1, 10,
or 100 nM wortmannin (Wm) for 30 min. Hepatocytes were then either left untreated
(NA) or treated with 80 nM insulin (Ins) or 20 µM sodium selenate (Se) for 42-48 h.
Cells from two plates were pooled and processed for each experimental condition, and
G6PDH activity was determined spectrophotometrically as change in the absorbance
ofNADPH. The activities of the control plates for each inhibitor concentration were
arbitrarily set at 100 %, and the effects of wortmannin with Ins or Se were expressed
as percent of control. Data shown is the mean of the specific activities (units/mg
protein)±S.E. ofthe number ofexperiments shown in parenthesis.

G6PDH activity by 23% at 10 nM of wortmannin, and this decrease was statistically
significant at p< 0.05. The activities ofthe control inhibitor plates were also compared
to control plates absent ofinhibitor. At concentrations of10 and 100 nM, percents of
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G6PDH activity as compared to control were 74 ± 12 and 59 ± 13, respectively.
These values are significantly lower than the control at p< 0.05, however, this did not
appear to be due to toxicity as seen with isocitrate dehydrogenase (ICDH) and lactate
dehydrogenase (LDH) activities. ICDH is a constitutively active enzyme in cellular
respiration. Decreases in the activity of this enzyme as compared to control samples
would indicate some cellular toxicity, and no appreciable differences were seen in
wortmannin-treated samples. Another general indicator of cellular toxicity is LDH
leakage into media. We would expect LDH activity to increase in media samples from
cells experiencing toxicity. Again, no appreciable differences were seen between
control samples and samples from wortmannin-treated samples.
After establishing involvement of PI 3-kinase, metabolic enzymes have been
found to signal through at least two different pathways, a rapamycin-sensitive route
and a rapamycin-insensitive route. Rapamycin has been used to determine S6 kinase
involvement with several insulin-regulated enzymes.

To determine if insulin and

selenium used a rapamycin-sensitive or rapamycin-insensitive pathway, rapamycin was
tested at 0.1, 1, and 10 nM. Primary rat hepatocytes in culture were incubated in the
absence or presence of rapamycin for 30 min and were then either left untreated or
treated with 80 nM insulin or 20 µM sodium selenate for 42-48 h. The activities of
the control plates for each inhibitor concentration were arbitrarily set at 100 %, and
the effects of rapamycin with insulin or selenate were expressed as percent of control.
Rapamycin did not significantly decrease insulin-induced G6PDH activity at any of the
concentrations tested (Table 2).

Rapamycin did, however, significantly decrease
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selenate-induced G6PDH activity. The activities of the control inhibitor plates were
also compared to control plates absent ofinhibitor. At 10 nM, the percent ofG6PDH
activity as compared to control was 70 ±5, which is a statistically significant decrease
from control tested at p < 0.05.
Table 2
Effect ofRapamycin on G6PDH Activity in Primary Rat Hepatocytes
Treatment

G6PDH activity as % ofcontrol

Ins

254±22 • (4)

Rap 0.1 + Ins

213±19 (4)

Rap 1 + Ins

216 (2)

Rap 10 + Ins

219±23 (4)

Se

209±16 • (4)

Rap 0.1 + Se

151±17 ° (4)

Rap 1 + Se

178 (2)

Rap 10 + Se

163±8 ° (3)

* Significantly different from NA at p<0.05.
0 Significantly different from Se at p<0.05.
Primary rat hepatocytes in culture were incubated in the absence or presence of0.1, 1,
or 10 nM rapamycin (Rap) for 30 min. Hepatocytes were then either left untreated
(NA) or treated with 80 nM insulin (Ins) or 20 µM sodium selenate (Se) for 42-48 h.
Cells from two plates were pooled and processed for each experimental condition, and
G6PDH activity was determined spectrophotometrically as change in the absorbance
ofNADPH. The activities of the control plates for each inhibitor concentration were
arbitrarily set at 100 %, and the effects ofrapamycin with Ins or Se were expressed as
percent ofcontrol. Data shown is the mean ofthe specific activities (units/mg protein)
±S.E. ofthe number ofexperiments shown in parenthesis.

DISCUSSION
Insulin has a wide range of metabolic and mitogenic effects in cells.
Metabolically, insulin is involved in such cellular processes as glucose uptake, fatty
acid synthesis, gluconeogenesis, gene expression, and glycogenesis. Disturbances of
any of these processes can have serious metabolic consequences.

Deficiencies in

synthesis or recognition of insulin by a cell has lead to interest in insulin-mimetic
agents that could potentially be used therapeutically to treat metabolic disorders such
as diabetes mellitus.

To understand whether or not a mimetic truly potentiates

properties similar to insulin, one must first understand the mechanism of insulin action.
Metabolic and growth-promoting effects of insulin on cells has been well-studied in the
past, and recently, much progress has been made on the signaling mechanism of insulin
(Myers & White, 1996; Kahn et al., 1993). Insulin's signaling pathway involves, at
least in part, a phosphorylation cascade. Insulin binds to its receptor causing tyrosine
autophosphorylation and activation of the receptor tyrosine kinase activity in the

P

subunit of the insulin receptor. IRS-1 is a substrate of the receptor kinase which
transmits the signal in a number of directions, including the MAP kinase cascade and
the PI 3-kinase pathway. Further downstream, the insulin signal causes nuclear events
such as DNA synthesis, protein synthesis, and gene expression.
Selenate has been shown to mimic insulin on several metabolic processes,
including regulation of blood glucose levels in streptozocin-induced diabetic rats (Berg
35
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et al., 1995; McNeil} et al., 1991), expression of insulin-regulated enzymes such as
G6PDH and fatty acid synthase in vivo (Berg et al., 1995) and in vitro (Stapleton et
al., unpublished data), and glucose transport (Furnsinn et al., 1996). The mechanism
of selenate action is not, however, known. We hypothesized that for selenate to mimic
G6PDH expression by insulin, the same signaling pathway should be utilized. To test
this hypothesis, we looked at the effects of insulin and selenate on signaling proteins in
the insulin signal transduction pathway in primary rat hepatocytes.

Primary rat

hepatocytes are an excellent model for these types of studies, since metabolically they
respond similarly to whole animal models.

Primary rat hepatocytes have not

previously been used to investigate insulin signaling using a metabolic end point such
as G6PDH expression. In addition, the effects of selenate on the signaling mechanism
of insulin has not yet been studied in this model system.
Insulin stimulates tyrosine phosphorylation in cells from insulin-sensitive
tissues (Myers & White, 1996; Kahn et al., 1993), and we chose to focus on two of
the most well-characterized tyrosyl phosphorylated proteins, the 13-subunit of the
insulin receptor and IRS-1. We show that insulin induced immediate increases in the
tyrosyl phosphorylation of a number of endogenous proteins, including the 13-subunit
of the insulin receptor and IRS-1. Insulin signaling of tyrosyl phosphorylation in
hepatocytes follows typical signaling mechanisms, that is, rapid initiation followed by
fairly rapid inhibition.

The results seen here do concur with the transient

phosphorylation seen with insulin receptors isolated from insulin-stimulated rat liver
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(Kowalski et al., 1983). The transient nature of insulin-induced phosphorylation is
most likely due to dephosphorylation by tyrosine phosphatases (Kowalski et al., 1983).
After establishing the increase in phosphorylation of the f3-subunit of the insulin
receptor and IRS-1, we next examined whether or not selenate could induce tyrosine
phosphorylation of these signal proteins.

Previous studies have shown selenate

stimulated tyrosyl phosphorylation in NIH 3T3 HIR3. 5 cells (Pillay & Makgoba,
1992) and adipocytes (Ezaki, 1990) using concentrations up to 1 mM selenate. We
found that 250 and 500 µM selenate initiated phosphorylation changes in the f3-subunit
of the insulin receptor and IRS-I in hepatocytes. The selenate-induced changes in
tyrosine phosphorylation of the f3-subunit phosphorylation and IRS-I were similar to
the increases seen with insulin. Parallel selenate studies were done in collaboration
with Adams & Kletzien in a different insulin-sensitive cell-type, 3T3-Ll adipocytes, to
show that selenate's effects were not specific to hepatic tissue (Stapleton et al., 1997).
In the 3T3-Ll cells, similar results concerning selenate-stimulated tyrosine
phosphorylation were obtained.

The increase in phosphorylation of IRS-I from

hepatocytes was not due to an increase in expression of the IRS-I protein as
determined by IRS-I immunoblots (Stapleton et al., 1997).

Generally, tyrosine

phosphorylation in response to selenate was a concentration and time-dependent
phenomenon in primary hepatocytes and in 3T3-Ll cells. There was a characteristic
delay in the appearance of phosphorylation. Even at 1 mM selenate, measurable
increases in phosphorylation took 30 minutes to appear (Ezaki, 1990). In addition,
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phosphorylation was not transient m nature, but in fact increased to extensive
proportions with continued incubation. This delay in onset and extensive degree of
phosphorylation were effects much different than those seen with insulin.
In experiments looking at tyrosine phosphorylation in our model and in the
3T3-Ll cells (Stapleton et al., 1997), there was consistently a massive tyrosine
phosphorylated band detected near 185 k:Da.

Although we confirmed, using

immunoprecipitation, that IRS-1 (Mr 185 k:Da) was a component of this signal,
questions arose as to whether or not this band could be the epidermal growth factor
(EGF) receptor, Mr 170 k:Da. EGF receptors are also abundant in hepatocytes, and
selenium has been reported to affect this receptor in A43l cells, however, 1 mM
selenate was required for phosphorylation (Pillay & Makgoba, 1992). To rule out the
possibility of this band being the EGF receptor, we tested the effect of PD 153035, a
specific inhibitor of the EGF receptor (Fry et al., 1994), on phosphorylation. Addition
of PD 153035 did not appear to have any effect on the selenate-induced tyrosyl
phosphorylation (data not shown). Thus, selenate does not appear to initiate its effect
on tyrosine phosphorylation through phosphorylation of the EGF receptor in our
model system.
Unlike insulin, selenate increased overall tyrosine phosphorylation to an
extensive level with continued incubation with cells. A potential cause of this degree
of phosphorylation could be cellular toxicity. Using LDH release into media and
fluorescent viability studies in which nonviable cells were identified by ethidium
bromide stained nuclei (Stapleton et al., unpublished data), we concluded that selenate
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was not toxic in pnmary rat hepatocytes with the concentrations used in these
experiments. Thus, the great degree of phosphorylation induced by selenate was not
in response to cellular toxicity.
An alternate explanation to the selenate-induced increase in tyrosine
phosphorylation involves possibly an increase in tyrosine kinase activity or a decrease
in tyrosine phosphatase activity. We used commercially available activity kits to try to
determine which activity may be affected. The tyrosine kinase activity kit did not give
meaningful results due to technical problems. The substrate supplied with the kit was
an amino acid sequence derived from pp60src. It is possible that selenate did not affect
kinases which were able to adequately phosphorylate the substrate for this kit.
However, it was most likely due to something in common to all samples, such as
procedure or reagents, since similar problems occurred with insulin-stimulated samples
and insulin is reportedly a good stimulator of phosphorylation of the substrate (Pike et
al., 1986). We could not draw conclusions concerning selenate's effect on tyrosine
kinase activity, however, Ezaki (1990) reports that, in a cell-free system, selenate did
not stimulate tyrosine kinase activity.
An inhibition of phosphatase activity seems like a feasible explanation because
of the delay in selenate induction of phosphorylation.

Inhibition of phosphatase

activity would allow phosphate concentrations to build up to the point of detection.
There is at least one report that selenate does not inhibit phosphotyrosine
phosphatases in a cell-free system (Ezaki, 1990). Although, interestingly, selenium
compounds are able to bind thiols (Ganther, 1968). Protein tyrosine phosphatases and
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dual-specificity phosphatases, which dephosphorylate tyrosine and serine/threonine
residues, contain a consensus sequence in their active site ofHCXXGXXRS(T) (Denu
& Dixon, 1995). Selenate could potentially bind the thiol of the cysteine residue,
rendering these classes of phosphatases inactive. We were unable to test selenate's
effects on tyrosine phosphatase activity, however, because this type of activity kit was
unavailable at the time of these experiments.

We did try a serine/threonine

phosphatase activity kit. Our reasoning for attempting this assay was that, since later
events in insulin signaling typically involve more serine/threonine phosphorylation, it's
possible that inhibition of downstream events could affect upstream tyrosine
phosphorylation events in a feedback fashion. Okadaic acid, a specific inhibitor ofPP1 and PP-2A serine/threonine phosphatases, showed substantial decreases in
phosphatase activity in treated cells, whereas the activity of these two phosphatases
was insensitive to selenate.
The induction of tyrosine phosphorylation by selenate illustrated differences in
kinetics as compared to insulin induction, specifically, a delay in the onset of
phosphorylation. Selenate does not appear to be binding to the insulin receptor, since
the rapid effects of autophosphorylation and initiation of the cascade were not seen.
The chemical configuration ofselenate is a tetrahedral arrangement, which is similar to
the shape of vanadate. It has been suggested that vanadate could act through a post
receptor mechanism (Blondel et al., 1990; Green, 1986), gaining entry into cells
through phosphate-like transport (Heinz et al., 1982). Ezaki (1990) has reported that
selenate does not activate the insulin receptor kinase activity in a cell-free system,
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although tyrosine phosphorylation of a 95 kDa protein was seen. Phosphorylation of
the insulin receptor does not necessarily mean activation, but is correlated with
activation. In the present studies and in the parallel studies with 3T3-Ll adipocytes
(Stapleton et al., 1997), we examined only phosphorylation of the receptor. The
possibility remains that activation of the receptor is not critical to initiate selenate's
mimetic effects. This phosphorylation may be a by-product of some other mechanism
of selenate action, or it may play some role in the sustained/amplified selenate
responses observed.
The MAP kinase family was a prominent family of kinases studied at the time
of these investigations. MAP kinases are conserved among many species and are
triggered by a variety of growth and stress stimuli (Seger et al., 1995; Ferrell, 1996).
These proteins were a logical choice for our study, since reports indicated that
members of the MAP kinase family are activated in response to insulin (Tobe et al.,
1992; Boulton et al., 1991). One well-defined cascade which activates MAP kinase is
the Ras/Raf/MEK cascade (Nishida & Gotoh, 1993).

Inhibitors have been used

extensively in characterizing this and other signaling pathways. One caution to keep in
mind when utilizing inhibitors is that "specific" inhibitors are not usually specific, in
that they often are found later to affect other proteins. However, inhibitors do give us
initial results on which to design further experiments and correlate subsequent results.
Lovastatin, an inhibitor of Ras famesylation (Hohl & Lewis, 1995), was one of the
earliest inhibitors used to investigate Ras participation in activation of the MAP kinase
cascade.
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In agreement with studies done with 3T3-Ll cells (Stapleton et al., 1997),
insulin increased activity ofMAP kinase over 2 fold that of control. The activation
was transient, increasing maximally with five minutes of stimulation and quickly
decreasing to basal. In primary rat heptocytes, insulin-induction of MAP kinase
activation seems to be Ras-dependent, since the highest concentration of lovastatin
significantly decreased activity. This decrease in MAP kinase activity by lovastatin is
probably not due to a decrease in MAP kinase expression, but is most likely due to a
decrease in activation resulting from reduced tyrosine phosphorylation (Xu et al.,
1996). Subsequent studies with B581, a Ras inhibitor distinct from that oflovastatin,
confirm the dependence of MAP kinase activity on Ras activation (Stapleton et al.,
unpublished data).
Now that we had established MAP kinase activation through a Ras-dependent
pathway, we investigated the effect ofselenate on the activation ofthis protein. MAP
kinase activation occurs with selenate in the present study in hepatocytes and in the
parallel study in 3T3-Ll adipocytes (Stapleton et al., 1997), although adipocytes
responded to a greater degree than hepatocytes. Selenate induction of MAP kinase
activity exhibited similar characteristics in both hepatocytes and 3T3-Ll cells
(Stapleton et al., 1997) as those seen with tyrosine phosphorylation in terms of the
delay ofonset ofactivity and sustained activity through later time points.
Selenate-induction of MAP kinase activation was significantly inhibited by
lovastatin, and these results have been subsequently confirmed with B581 (Stapleton
et al., unpublished data). Thus, MAP kinase activation by selenate, like insulin, appears

43
to be Ras-dependent. There have been no reports to date concerning the pathway by
which selenate signals MAP kinase activation, however, vanadate has been shown to
activate MAP kinase in HeLa cells through Ras (Zhao et al., 1996). Vanadate, a
tyrosine phosphatase inhibitor, increased MAP kinase activity, and this activity was
sustained in a manner to that seen in our current study with selenate. Inhibition of
tyrosine phosphatase activity was sufficient to initiate the complete MAP kinase
cascade (Zhao et al., 1996).

Although Ezaki (1990) reported no inhibition of

phosphotyrosine phosphatase activity by selenate in a cell-free system, selenate could
potentially inactivate tyrosine phosphatases in vivo by binding to the active site thiol,
thereby activating MAP kinase.
Since we had established the phosphorylation of signal proteins in response to
insulin and selenate, initial experiments were carried out to determine whether or not
the increase in phosphorylation could mediate a downstream metabolic event such as
regulation of G6PDH expression. G6PDH expression is upregulated by insulin (Berg
et al., 1995), but the signaling pathway that gives rise to increased expression is not
known. In order to characterize a potential signaling pathway for expression of
G6PDH, inhibitors were again employed. Inhibitors used in this set of experiments
were lovastatin, wortmannin (a PI 3-kinase inhibitor), and rapamycin (an S6 kinase
inhibitor). We utilized these inhibitors in an attempt to block the known pathways of
insulin signaling to determine the effect on G6PDH expression. Inhibitors are not the
best approach for these types of experiments because of their lack of specificity,
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however, these were the tools that were available at the time of this study, and they
were some of the few tools that can be utilized with our primary cell cultures.
MAP kinase activity was elevated in response to insulin, and this potentially
has importance in mediating many of insulin's effects. In order to determine if the
increase in MAP kinase activity was linked to G6PDH expression, the inhibitor
lovastatin was used. Lovastatin did not have any effect on insulin-stimulated G6PDH
activity. Thus, MAP kinase appears to not be involved in G6PDH expression by
insulin. Subsequently, both B581 and PD 098059, a specific inhibitor ofMEK (Alessi
et al., 1995), have been used (Stapleton et al., unpublished data), and the results
confirm that the MAP kinase pathway is not involved. These results are in agreement
with other studies attempting to link the MAP kinase pathway to metabolic events.
Recently, it has been shown that inhibition of the MAP kinase pathway had no effect
on PEPCK expression in H4IIE cells (Gabbay et al., 1996), as well as no effect on
glucose uptake in 3T3-Ll cells or glycogen synthase in 3T3-Ll cells and M6 myocytes
(Lazar et al., 1995).
With evidence against MAP kinase participation in G6PDH expression, our
attention turned to the PI 3-kinase pathway as a potential link to expression. The PI
3-kinase pathway has been associated with some of the metabolic effects of insulin.
Wortmannin and rapamycin have been used to study glycogen synthase activity
(Shepard et al., 1995), PEPCK gene expression (Sutherland et al., 1995), and glucose
transporter activity (Moule et al., 1995). The use of these inhibitors has helped in the
discovery of at least two signaling branches from PI 3-kinase in insulin stimulation, a
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rapamycin-sensitive pathway and a rapamycin-insensitive pathway.

Many of the

metabolic enzymes are now being characterized in accordance to these pathways.
Wortmannin significantly decreased G6PDH activity induced by insulin. Thus,
it appears that PI 3-kinase participates in insulin-induced G6PDH expression. The two
highest concentrations of wortmannin did, however, significantly lower endogenous
G6PDH activity in unstimulated cells. This did not appear to be due to toxicity. After
experiments had been concluded, reports indicated a stability problem with
wortmannin when incubated for lengths of time (Kimura et al., 1994), and this problem
is successfully circumvented by replacing wortmannin in media every two hours
(Gabbay et al., 1996). Keeping these results in mind, it is difficult to draw substantial
conclusions from the experiments with wortmannin.
Rapamycin did not significantly decrease insulin induction of G6PDH
expression. Thus, these results indicate that insulin regulation of G6PDH expression
may not be through a rapamycin-sensitive pathway. Subsequent studies in the lab,
however, show regulation of G6PDH expression to be rapamycin-sensitive (Stapleton
et al., unpublished data). Explanations for this discrepancy are not clear, however, it
could be due to times of incubation with rapamycin.

Further investigations are

necessary to determine rapamycin's effects on insulin-induced G6PDH expression.
Parallel inhibitor studies were done to test which signal proteins might be
involved in selenate induction of G6PDH expression.

Results show that both

wortmannin and rapamycin significantly decreased selenate-stimulated G6PDH
expression. Again, involvement of PI 3-kinase in G6PDH expression in selenate-
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stimulated cells is uncertain because of instability of wortmannin under our
experimental conditions, however, selenate appears to signal increases m G6PDH
expression through a rapamycin-sensitive pathway.
In summary, selenate mimics insulin action on a number of metabolic
processes, however, the mechanism of action is unknown.
selenate and insulin signaling share some similarities.

It appears as though

Tyrosine phosphorylation

increases in two of the early signaling proteins in the insulin phosphorylation cascade,
the �-subunit of the insulin receptor and IRS-1. MAP kinase is substantially activated
through a Ras-dependent mechanism. Initial evidence suggests increases in G6PDH
expression are a result of signaling events transmitted through the PI 3-kinase pathway
and possibly through a rapamycin-sensitive pathway, however, more studies are
needed for signal pathway characterization of this metabolic event.

Insulin and

selenate signaling mechanisms also have differences. Effects of selenate are first seen
at much later time points than that of insulin, and the effects are sustained over long
periods of time.

Several signaling proteins are affected by selenate, and selenate

signaling is somewhat cascade-like because of the fact that inhibitors affect
downstream targets. However, selenate acts with less specificity than insulin and with
less regulation as compared to the tightly regulated, transient effects seen in response
to insulin. Further studies will help fully define the role selenate plays in insulin
mimicking actions on metabolic events.

Appendix A
Protocol Clearance From the Institutional
Animal Care and Use Committee
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